New trial
Phase 1/2a VS-7375 trial: KRAS G12D inhibitor for advanced solid tumors
- Trial ID
- NCT07020221 on ClinicalTrials.gov
- Cancer type
- Other Solid Tumors
- Stage of research
- First-in-human
- Location
- 3 Locations
- Published in
- New in Oncology - July 3, 2025
This open-label study evaluates VS-7375 alone or with cetuximab in patients with advanced metastatic solid tumors harboring KRAS G12D mutations, including pancreatic, lung, and colorectal cancers. The trial aims to determine the optimal dosing and assess preliminary safety and efficacy, and is conducted at sites in Nashville, Houston, and Seattle by Verastem, Inc.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings